Humanized antibodies that sequester abeta peptide

Details for Australian Patent Application No. 2001241786 (hide)

Owner Eli Lilly and Company Washington University

Inventors Bales, Kelly R.; Tsurushita, Naoya; Demattos, Ronald; Paul, Steven M.; Vasquez, Maximiliano; Holtzman, David M.

Agent Spruson & Ferguson

Pub. Number AU-B-2001241786

PCT Pub. Number WO01/62801

Priority 60184601 24.02.00 US; 60254465 08.12.00 US; 60254498 08.12.00 US

Filing date 26 February 2001

Wipo publication date 3 September 2001

Acceptance publication date 22 February 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12R 1/91 (2006.01)

Event Publications

22 February 2007 Application Accepted

  Published as AU-B-2001241786

21 June 2007 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001241789

2001241785